Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Homes 4 Rent Class A (AMH) vs Heron Therapeutics Inc (HRTX) Price & Performance

American Homes 4 Rent Class A
Heron Therapeutics Inc

Price performance

Price movement over the last 24 hours

Key statistics

American Homes 4 Rent Class A vs Heron Therapeutics Inc — how do they compare? American Homes 4 Rent Class A trades at $33.27 (market cap $11.97B), while Heron Therapeutics Inc trades at $0.42 (market cap $79.52M). The key difference: American Homes 4 Rent Class A is far larger — about 150.5× Heron Therapeutics Inc's market cap, and American Homes 4 Rent Class A pays a 3.97% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

AMHHRTX
Market Cap
$11.97B$79.52M
Sector
Real EstateHealth
52-Week High
$36.74$2.18
52-Week Low
$27.38$0.39
Enterprise Value
$17.05B$177.42M
Dividend Yield
3.97%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Homes 4 Rent Class A

AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.

Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.

Heron Therapeutics Inc

HRTX trades at $0.4144, down 3.29% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $154.9M with a net loss of $20.2M, missing EPS expectations. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 94.7% buy ratings. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite seasonal headwinds.

The stock faces fundamental challenges with negative earnings and cash flow, but strong analyst support and patent protection for key products provide potential upside. Key risks include ongoing operational losses and competitive pressures in the biotechnology sector. The current valuation at 0.46 P/S suggests potential if the company can achieve profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Homes 4 Rent Class A

American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas

Read more on AMH

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX